ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
The Danger of 'Going too far' with AI
Andrew Garrett spoke on a panel at the Financial Times Pharmaceutical & Biotechnology conference, about the recent integration of artificial intelligence (AI) enabled services in pharma R&D.
Risk-Based Monitoring and Real-World Data: A Decentralised Ecosystem
Ian O'Shaughnessy considers how to ensure a reality for the bright future of digitisation as clinical trials evolve.
Trends in Payer Reliance on ICER Assessments
A thought leadership authored by Jenny Lee and Eric Latch, based on the ICON’s whitepaper “Payer reliance on ICER assessments and perceptions on value-based pricing”.
A Strategic Business Plan to ensure success under MDR/IVDR
David Novotny and Angela Brown outline how manufacturers can develop a strategic business model that will prepare them for success under new MDR/IVDR reforms.
Using Clinical Decision Support Tools To Facilitate Decision-Making In Precision Medicine
This article featured in Forbes considers how technology – particularly AI and big data – can enable precision medicine.
Trends in Biosimilar Market Access
A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.
Biomarker-driven Landscape in Clinical Trials
An interview with Nicole Cowan covering the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.
Social Media Outreach
ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of PharmaVoice.
Making it Easier for the Site to Succeed
A thought leadership article authored by EB McLindon, discussing how making clinical research easier for the site can also make life easier for sponsors.
NASH Clinical Trials – An Outlook on Challenges and Advances
Andrew Roche discusses the challenges of delayed diagnosis, and under diagnosis, of NASH, the impact on NASH clinical trials, and important NASH endpoints being considered.